Patents by Inventor James Moncrief
James Moncrief has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11993681Abstract: A method for purifying a contaminated reclaimed polyethylene is provided. The method comprises obtaining the contaminated reclaimed polyethylene, extracting it with a solvent to produce an extracted contaminated reclaimed polyethylene, and then dissolving it in the solvent to produce a first suspension comprising dissolved polyethylene and suspended contaminants. The first suspension is settled to produce a second suspension comprising dissolved polyethylene and suspended remaining contaminants, and the second suspension is purified by contacting it with solid media to produce a third suspension comprising purer polyethylene. Finally, the purer polyethylene is separated from the third suspension and it has virgin-like optical properties.Type: GrantFiled: March 15, 2023Date of Patent: May 28, 2024Assignee: The Procter & Gamble CompanyInventors: Dimitris Ioannis Collias, Amy Eichstadt Waun, James Carmony, John Moncrief Layman
-
Patent number: 11993680Abstract: A method for purifying a contaminated reclaimed HDPE is provided. The method comprises obtaining the contaminated reclaimed HDPE, extracting it with a solvent to produce an extracted contaminated reclaimed HDPE, and then dissolving it in the solvent to produce a first suspension comprising dissolved HDPE and suspended contaminants. The first suspension is settled to produce a second suspension comprising dissolved HDPE and suspended remaining contaminants, and the second suspension is purified by contacting it with solid media to produce a third suspension comprising purer HDPE. Finally, the purer HDPE is separated from the third suspension and it has natural-like optical properties.Type: GrantFiled: March 2, 2023Date of Patent: May 28, 2024Assignee: The Procter & Gamble CompanyInventors: Dimitris Ioannis Collias, Amy Eichstadt Waun, James Carmony, John Moncrief Layman
-
Patent number: 11993682Abstract: A method for purifying a contaminated reclaimed HDPE is provided. The method comprises obtaining the contaminated reclaimed HDPE, extracting it with a solvent to produce an extracted contaminated reclaimed HDPE, and then dissolving it in the solvent to produce a first suspension comprising dissolved HDPE and suspended contaminants. The first suspension is settled to produce a second suspension comprising dissolved HDPE and suspended remaining contaminants, and the second suspension is purified by contacting it with solid media to produce a third suspension comprising purer HDPE. Finally, the purer HDPE is separated from the third suspension and it has natural-like optical properties.Type: GrantFiled: March 15, 2023Date of Patent: May 28, 2024Assignee: The Procter & Gamble CompanyInventors: Dimitris Ioannis Collias, Amy Eichstadt Waun, James Carmony, John Moncrief Layman
-
Publication number: 20240158990Abstract: A biodegradable and recyclable barrier paper laminate comprising an inorganic barrier layer against permeation.Type: ApplicationFiled: January 23, 2024Publication date: May 16, 2024Inventors: Emily Charlotte BOSWELL, Uwe BOLZ, Patti Jean KELLETT, James Terry KNAPMEYER, Pier-Lorenzo CARUSO, Lee Mathew ARENT, John Moncrief LAYMAN, Jack Alan HUNTER
-
Patent number: 11913173Abstract: A biodegradable and recyclable barrier paper laminate comprising an inorganic barrier layer against permeation.Type: GrantFiled: October 7, 2021Date of Patent: February 27, 2024Assignee: The Procter & Gamble CompanyInventors: Emily Charlotte Boswell, Uwe Bolz, Patti Jean Kellett, James Terry Knapmeyer, Pier-Lorenzo Caruso, Lee Mathew Arent, John Moncrief Layman, Jack Alan Hunter
-
Publication number: 20080091467Abstract: A system, pharmacy management software, and related methods of enhanced pharmaceutical operations in patient care facilities are provided. The pharmacy management software, for example, can include instructions that when executed by a computer, cause the computer to perform the operations of providing instructions to pharmaceutical storage and electronic dispensing carts positioned at various patient care facilities according to patient specific prescription requirements, receiving dispensing data from each of the carts, and providing separate billing records including billing data indexed by reimbursement provider for each patient at the patient care facilities. The operations can also include consolidating the billing data by patient, by patient care facility, by remote pharmacy, and/or consolidating billing data by reimbursement provider, and submitting separate consolidated reimbursement claims electronically to each respective reimbursement provider.Type: ApplicationFiled: December 5, 2007Publication date: April 17, 2008Applicant: Tech Pharmacy Services, Inc.Inventors: James Moncrief, James Martin
-
Publication number: 20080090771Abstract: The invention relates to compounds, compositions and methods comprised of a chemical moiety attached to hydrocodone. The invention provides embodiments that provide a decrease in the potential of hydrocodone to cause overdose or to be abused while still delivering therapeutic activity similar to that of the parent hydrocodone. The invention also provides methods of delivering hydrocodone as conjugates that release the hydrocodone following oral administration while being resistant to abuse by other routes such as intravenous injection (“shooting”) and intranasal administration (“snorting”). Further, hydrocodone compositions of the invention are resistant to oral abuse as well, since release of the hydrocodone at suprapharmacological doses reaches saturation.Type: ApplicationFiled: October 8, 2007Publication date: April 17, 2008Applicant: SHIRE LLCInventor: James Moncrief
-
Publication number: 20080086016Abstract: The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Type: ApplicationFiled: May 7, 2007Publication date: April 10, 2008Applicant: New River Pharmaceuticals Inc.Inventors: Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Moncrief, Robert Oberlender, Thomas Piccariello, Bernhard Paul, Christopher Verbicky
-
Publication number: 20070250210Abstract: A system, software and related methods of enhanced pharmaceutical operations in long term care facilities are provided. An embodiment of a system includes a long-term care facility pharmacy group management server, long-term care facility pharmacy management software associated with the long-term care facility pharmacy group management server to manage pharmacological operations in a plurality of long-term care facilities, a plurality of pharmaceutical storage and electronic dispensing carts each positioned in a long-term care facility remote from the long-term care facility pharmacy group management server and in communication therewith, a remote pharmacy group server in communication with the long-term care facility pharmacy group management server, and a plurality of pharmaceutical prescription document processors each positioned in a long-term care facility and in communication with the remote pharmacy group server or the long-term care facility pharmacy group management server.Type: ApplicationFiled: June 14, 2007Publication date: October 25, 2007Inventors: James Moncrief, James Martin
-
Publication number: 20070232529Abstract: The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.Type: ApplicationFiled: August 23, 2004Publication date: October 4, 2007Applicant: New River Pharmaceuticals Inc.Inventors: Travis Mickle, Suma Krishnan, James Moncrief, Christopher Lauderback, Thomas Piccariello, Randal Kirk
-
Publication number: 20070197451Abstract: The invention provides a “street-safe” version of a controlled substance that permits the therapeutically beneficial effects of the substance while reducing or eliminating the euphoric effects that lead to substance abuse. The invention provides pharmaceutical compositions comprising a controlled substance and a carbohydrate covalently bound to said controlled substance in a manner that renders said controlled substance pharmacologically inactive or substantially diminishes its activity and methods of using the same.Type: ApplicationFiled: July 13, 2005Publication date: August 23, 2007Inventors: Travis Mickle, Thomas Piccariello, James Moncrief, Nancy Boerth, Barney Bishop
-
Publication number: 20070099841Abstract: The invention relates to compositions of amino acid and peptide conjugates comprising T3 and/or T4. The T3 or T4 is covalently attached to at least one amino acid via the N-terminus, the C-terminus, a side chain of the peptide carrier, and/or interspersed within the peptide chain. Also discussed are methods for protecting and administering active agents and methods for treating thyroid disorders.Type: ApplicationFiled: September 8, 2006Publication date: May 3, 2007Applicant: New River Pharmaceuticals Inc.Inventors: James Moncrief, Travis Mickle, Lawrence Olon, Thomas Piccariello
-
Publication number: 20070066537Abstract: The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to an opioid such as oxycodone in a manner that substantially decreases the potential of the opioid to cause overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent. Further the compounds and compositions of the invention are useful in preventing addiction and susceptibility to addiction.Type: ApplicationFiled: September 30, 2004Publication date: March 22, 2007Applicant: New River Pharmaceuticals Inc.Inventors: Travis Mickle, Suma Krishnan, James Moncrief, Christopher Lauderback, Thomas Piccariello, Sanjib Bera, Sven Guenther, Wendy Hirschelman
-
Publication number: 20070060500Abstract: The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.Type: ApplicationFiled: March 30, 2006Publication date: March 15, 2007Applicant: New River Pharmaceuticals Inc.Inventors: Travis Mickle, Suma Krishnan, James Moncrief, Christopher Lauderback, Christal Miller, Thomas Piccariello
-
Publication number: 20070042955Abstract: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Type: ApplicationFiled: April 10, 2006Publication date: February 22, 2007Applicant: New River Pharmaceuticals Inc.Inventors: Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Moncrief, Rob Oberlender, Thomas Piccariello
-
Publication number: 20060014697Abstract: The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.Type: ApplicationFiled: March 25, 2005Publication date: January 19, 2006Inventors: Travis Mickle, Suma Krishnan, James Moncrief, Christopher Lauderback
-
Publication number: 20050266070Abstract: The present invention decreases the potential for abuse of opioids, particularly hydrocodone, by covalent modification. The invention provides methods of delivering hydrocodone as conjugates that release the hydrocodone following oral administration while being resistant to abuse by circuitous routes such as intravenous (“shooting”) injection and intranasal administration (“snorting”). Further, hydrocodone compositions of the invention are resistant to oral abuse as well, since release of the hydrocodone at suprapharmacological doses reaches saturation.Type: ApplicationFiled: September 30, 2004Publication date: December 1, 2005Applicant: New River Pharmaceuticals Inc.Inventors: Travis Mickle, Suma Krishnan, James Moncrief, Christopher Lauderback, Christal Miller
-
Publication number: 20050176645Abstract: The present invention decreases the potential for abuse of opioids, particularly hydrocodone, by covalent modification. The invention provides methods of delivering hydrocodone as conjugates that release the hydrocodone following oral administration while being resistant to abuse by circuitous routes such as intravenous (“shooting”) injection and intranasal administration (“snorting”). Further, hydrocodone compositions of the invention are resistant to oral abuse as well, since release of the hydrocodone at suprapharmacological doses reaches saturation.Type: ApplicationFiled: September 30, 2004Publication date: August 11, 2005Applicant: New River Pharmaceuticals Inc.Inventors: Travis Mickle, Suma Krishnan, James Moncrief, Christal Miller, Christopher Lauderback, Thomas Piccariello
-
Publication number: 20050176644Abstract: The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to an opioid such as oxycodone in a manner that substantially decreases the potential of the opioid to cause overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent. Further the compounds and compositions of the invention are useful in preventing addiction and susceptibility to addiction.Type: ApplicationFiled: September 30, 2004Publication date: August 11, 2005Applicant: New River Pharmaceuticals Inc.Inventors: Travis Mickle, Suma Krishnan, James Moncrief, Christopher Lauderback, Sanjib Bera, Sven Guenther, Wendy Hirschelman
-
Publication number: 20050176646Abstract: The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.Type: ApplicationFiled: September 30, 2004Publication date: August 11, 2005Applicant: New River Pharmaceuticals Inc.Inventors: Travis Mickle, Suma Krishnan, James Moncrief, Christopher Lauderback, Christal Miller